
Michael N Pollak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8639656/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. International Journal of Epidemiology, 2023, 52, 71-86.	0.9	16
2	Clinically Relevant Circulating Protein Biomarkers for Type 1 Diabetes: Evidence From a Two-Sample Mendelian Randomization Study. Diabetes Care, 2022, 45, 169-177.	4.3	18
3	Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial. Endocrine-Related Cancer, 2022, 29, 99-109.	1.6	8
4	Biomarkers of Glucose Homeostasis and Inflammation with Risk of Prostate Cancer: A Case–Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 736-743.	1.1	0
5	Mitochondrial complex IV defects induce metabolic and signaling perturbations that expose potential vulnerabilities in HCT116 cells. FEBS Open Bio, 2022, 12, 959-982.	1.0	2
6	Circulating Insulin-Like Growth Factor 1–Related Biomarkers and Risk of Lethal Prostate Cancer. JNCI Cancer Spectrum, 2022, 6, pkab091.	1.4	6
7	Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a populationâ€based cohort. Cancer, 2022, 128, 1365-1372.	2.0	4
8	Metformin-induced reductions in tumor growth involves modulation of the gut microbiome. Molecular Metabolism, 2022, 61, 101498.	3.0	21
9	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2021, 5, pkaa074.	1.4	6
10	A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. Nature Medicine, 2021, 27, 659-667.	15.2	188
11	Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations. Npj Breast Cancer, 2021, 7, 18.	2.3	5
12	Effects of Adiposity and Exercise on Breast Tissue and Systemic Metabo-Inflammatory Factors in Women at High Risk or Diagnosed with Breast Cancer. Cancer Prevention Research, 2021, 14, 541-550.	0.7	13
13	Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence: A Nested Case-Control Study. Frontiers in Oncology, 2021, 11, 626058.	1.3	6
14	Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin. Neoplasia, 2021, 23, 391-399.	2.3	18
15	Association of plasma adiponectin with tumor infiltrating lymphocytes and survival in patients with stage III colon cancer (NCCTG N0147; Alliance) Journal of Clinical Oncology, 2021, 39, 3591-3591.	0.8	1
16	Clinicopathologic features of breast cancers diagnosed in females treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort Journal of Clinical Oncology, 2021, 39, 567-567.	0.8	0
17	STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. Nature Communications, 2021, 12, 3299.	5.8	24
18	The role of GSK3 in metabolic pathway perturbations in cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 119059.	1.9	20

#	Article	IF	CITATIONS
19	Blood biomarkers reflect the effects of obesity and inflammation on the human breast transcriptome. Carcinogenesis, 2021, 42, 1281-1292.	1.3	5
20	Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. JNCI Cancer Spectrum, 2021, 5, pkab070.	1.4	4
21	A hydride transfer complex reprograms NAD metabolism and bypasses senescence. Molecular Cell, 2021, 81, 3848-3865.e19.	4.5	24
22	Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report. Journal of Cancer Prevention, 2021, 26, 309-317.	0.8	1
23	Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. British Journal of Cancer, 2020, 122, 258-265.	2.9	28
24	Pilot Study Assessing Tolerability and Metabolic Effects of Metformin in Patients With Li-Fraumeni Syndrome. JNCI Cancer Spectrum, 2020, 4, pkaa063.	1.4	6
25	Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. Cancer Prevention Research, 2020, 13, 1055-1062.	0.7	17
26	Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 999-1008.	1.1	19
27	Subclinical hypothyroidism and the risk of cancer incidence and cancer mortality: a systematic review. BMC Endocrine Disorders, 2020, 20, 83.	0.9	16
28	Repression of LKB1 by miR-17â^1⁄492 Sensitizes MYC-Dependent Lymphoma to Biguanide Treatment. Cell Reports Medicine, 2020, 1, 100014.	3.3	16
29	Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors. JNCI Cancer Spectrum, 2020, 4, pkz096.	1.4	14
30	A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index. Cancer Prevention Research, 2020, 13, 203-212.	0.7	21
31	Prediagnostic use of lowâ€dose aspirin and risk of incident metastasis and allâ€cause mortality among patients with colorectal cancer. British Journal of Clinical Pharmacology, 2020, 86, 2266-2273.	1.1	3
32	Cancer Immunoprevention: A Case Report Raising the Possibility of "Immuno-interception― Cancer Prevention Research, 2020, 13, 351-356.	0.7	7
33	Prospective Association of Energy Balance Scores Based on Metabolic Biomarkers with Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 974-981.	1.1	1
34	Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia. Journal of Molecular Endocrinology, 2019, 62, R83-R103.	1.1	9
35	Relationship of circulating insulin-like growth factor-I and binding proteins 1–7 with mammographic density among women undergoing image-guided diagnostic breast biopsy. Breast Cancer Research, 2019, 21, 81.	2.2	10
36	High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome. Gastroenterology, 2019, 157, 492-506.e2.	0.6	100

#	Article	IF	CITATIONS
37	Plasma Biomarkers of Insulin and the Insulin-like Growth Factor Axis, and Risk of Colorectal Adenoma and Serrated Polyp. JNCI Cancer Spectrum, 2019, 3, pkz056.	1.4	9
38	elF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. Nature Communications, 2019, 10, 5151.	5.8	64
39	Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression. Clinical Cancer Research, 2019, 25, 7229-7242.	3.2	26
40	Cancer Prevention. Cancer Prevention Research, 2019, 12, 1-2.	0.7	1
41	Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. Journal of the National Cancer Institute, 2019, 111, 970-982.	3.0	43
42	Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. Clinical Genitourinary Cancer, 2019, 17, e323-e328.	0.9	23
43	The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGFâ€I, IGFâ€I, IGFBPâ€1, IGFBPâ€2 and IGFBPâ€3 in a pooled analysis of 16,024 men from 22 studies. International Journal of Cancer, 2019, 145, 3244-3256.	2.3	14
44	Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. BMC Cancer, 2019, 19, 1133.	1.1	14
45	mTOR as a central regulator of lifespan and aging. F1000Research, 2019, 8, 998.	0.8	244
46	Serum insulinâ€like growth factor (IGF)â€l and IGF binding proteinâ€3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank. International Journal of Cancer, 2018, 143, 496-507.	2.3	8
47	Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. Aging Cell, 2018, 17, e12723.	3.0	113
48	Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes. Epidemiology, 2018, 29, 246-253.	1.2	15
49	Trajectories of IGF-I Predict Mortality in Older Adults: The Cardiovascular Health Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 953-959.	1.7	18
50	Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. Cell Metabolism, 2018, 28, 679-688.e4.	7.2	92
51	Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. Cell Metabolism, 2018, 28, 817-832.e8.	7.2	61
52	A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. GeroScience, 2018, 40, 419-436.	2.1	221
53	Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer. Cell Reports, 2018, 24, 47-55.	2.9	48
54	Interplay between ShcA Signaling and PGC-1α Triggers Targetable Metabolic Vulnerabilities in Breast Cancer. Cancer Research, 2018, 78, 4826-4838.	0.4	10

#	Article	IF	CITATIONS
55	Diet boosts the effectiveness of a cancer drug. Nature, 2018, 560, 439-440.	13.7	5
56	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis, 2018, 39, 1431-1437.	1.3	35
57	Simultaneous Extraction of RNA and Metabolites from Single Kidney Tissue Specimens for Combined Transcriptomic and Metabolomic Profiling. Journal of Proteome Research, 2018, 17, 3039-3049.	1.8	13
58	Insulin-like growth factor 1 receptor stabilizes the ETV6–NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation. Journal of Biological Chemistry, 2018, 293, 12502-12515.	1.6	11
59	A phenotype of IGFBPâ€3 knockout mice revealed by dextran sulfateâ€induced colitis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 146-153.	1.4	6
60	Serum C-peptide, Total and High Molecular Weight Adiponectin, and Pancreatic Cancer: Do Associations Differ by Smoking?. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 914-922.	1.1	11
61	Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index. Cancer Prevention Research, 2017, 10, 235-243.	0.7	114
62	Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis. Nature Reviews Clinical Oncology, 2017, 14, 268-268.	12.5	3
63	Circulating levels of obesity-related markers and risk of renal cell carcinoma in the PLCO cancer screening trial. Cancer Causes and Control, 2017, 28, 801-807.	0.8	20
64	Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1692-1701.	1.8	77
65	Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease. Obesity, 2017, 25, 1317-1320.	1.5	17
66	Menstrual cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal women. Cancer Causes and Control, 2017, 28, 1441-1452.	0.8	16
67	The Association Between IGF-I and IGFBP-3 and Incident Diabetes in an Older Population of Men and Women in the Cardiovascular Health Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4541-4547.	1.8	10
68	Circulating resistin levels and risk of multiple myeloma in three prospective cohorts. British Journal of Cancer, 2017, 117, 1241-1245.	2.9	12
69	The effects of metformin on gut microbiota and the immune system as research frontiers. Diabetologia, 2017, 60, 1662-1667.	2.9	79
70	Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival. Annals of Surgical Oncology, 2017, 24, 3212-3219.	0.7	7
71	Periprostatic adipose inflammation is associated with high-grade prostate cancer. Prostate Cancer and Prostatic Diseases, 2017, 20, 418-423.	2.0	62
72	Insulinlike Growth Factor Binding Protein-1 and Ghrelin Predict Health Outcomes Among Older Adults: Cardiovascular Health Study Cohort. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 267-278.	1.8	14

#	Article	IF	CITATIONS
73	Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?. Nature Reviews Clinical Oncology, 2017, 14, 85-99.	12.5	163
74	Effects of Rapid Weight Loss on Systemic and Adipose Tissue Inflammation and Metabolism in Obese Postmenopausal Women. Journal of the Endocrine Society, 2017, 1, 625-637.	0.1	54
75	Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. Nutrients, 2017, 9, 378.	1.7	14
76	Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. Journal of Clinical Oncology, 2017, 35, 3647-3653.	0.8	40
77	Multicenter, randomized phase II trial of physical activity (PA), metformin (Met), or the combination on metabolic biomarkers in stage I-III colorectal (CRC) and breast cancer (BC) survivors Journal of Clinical Oncology, 2017, 35, 10059-10059.	0.8	1
78	Metformin to treat prostate cancer (PCa) and prevent metabolic syndrome associated with androgen deprivation therapy (ADT): Results of a randomized double-blind placebo-controlled study of metformin in non-diabetic men initiating ADT for advanced PCa Journal of Clinical Oncology, 2017, 35, e16502-e16502.	0.8	2
79	Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. Oncotarget, 2017, 8, 50542-50556.	0.8	21
80	Metabolic heterogeneity signature of primary treatment-naÃ⁻ve prostate cancer. Oncotarget, 2017, 8, 25928-25941.	0.8	16
81	Incidence of periprostatic white adipose tissue inflammation in men with prostate cancer Journal of Clinical Oncology, 2017, 35, 63-63.	0.8	0
82	Influence of Fasting Status and Sample Preparation on Metabolic Biomarker Measurements in Postmenopausal Women. PLoS ONE, 2016, 11, e0167832.	1.1	10
83	Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). Oncotarget, 2016, 7, 65643-65659.	0.8	35
84	Exercise and Prostate Cancer: Evidence and Proposed Mechanisms for Disease Modification. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1281-1288.	1.1	22
85	Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer. European Urology, 2016, 70, 808-815.	0.9	27
86	Agreement between circulating IGF-I, IGFBP-1 and IGFBP-3 levels measured by current assays versus unavailable assays previously used in epidemiological studies. Growth Hormone and IGF Research, 2016, 26, 11-16.	0.5	6
87	Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?. Cell Metabolism, 2016, 23, 569-570.	7.2	140
88	Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. Breast Cancer Research and Treatment, 2016, 157, 101-108.	1.1	0
89	Genomewide metaâ€analysis identifies loci associated with <scp>IGF</scp> â€I and <scp>IGFBP</scp> â€3 levels with impact on ageâ€related traits. Aging Cell, 2016, 15, 811-824.	3.0	83
90	Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Cancer Research, 2016, 76, 7160-7167.	0.4	46

#	Article	IF	CITATIONS
91	Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. BMJ, The, 2016, 355, i5340.	3.0	13
92	Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. Breast Cancer Research, 2016, 18, 1.	2.2	110
93	Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. Breast Cancer Research, 2016, 18, 24.	2.2	18
94	nanoCAGE reveals 5′ UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs. Genome Research, 2016, 26, 636-648.	2.4	177
95	Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals. Cancer Research, 2016, 76, 1935-1941.	0.4	30
96	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Research, 2016, 76, 2288-2300.	0.4	117
97	High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with â^1⁄4240-Fold Higher Drug Concentration in Urine than Serum. Molecular Cancer Therapeutics, 2016, 15, 430-438.	1.9	16
98	Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. Clinical Cancer Research, 2016, 22, 2283-2289.	3.2	154
99	Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to <i>KRAS</i> Mutation Status. Journal of the National Cancer Institute, 2016, 108, djv363.	3.0	37
100	Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. Journal of Clinical Investigation, 2016, 127, 132-136.	3.9	39
101	Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL) Tj ETQq1 1 Oncology, 2016, 34, TPS5092-TPS5092.	0.784314 0.8	4 rgBT /Over 9
102	IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias. PLoS ONE, 2016, 11, e0161158.	1.1	39
103	Pioglitazone and the risk of prostate cancer Journal of Clinical Oncology, 2016, 34, e16574-e16574.	0.8	0
104	Similarity of Serum and Plasma Insulin-like Growth Factor Concentrations. Biomarkers in Cancer, 2015, 7, BIC.S23088.	3.6	6
105	Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. Journal of Cancer Epidemiology, 2015, 2015, 1-7.	0.5	3
106	The Use of Aspirin and the Risk of Mortality in Patients with Prostate Cancer. Journal of Urology, 2015, 193, 1220-1225.	0.2	25
107	Germ line knockout of IGFBP-3 reveals influences of the gene on mammary gland neoplasia. Breast Cancer Research and Treatment, 2015, 149, 577-585.	1.1	15
108	mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle, 2015, 14, 473-480.	1.3	397

#	Article	IF	CITATIONS
109	Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms. Diabetes, 2015, 64, 1632-1642.	0.3	80
110	Circulating Leptin and Risk of Pancreatic Cancer: A Pooled Analysis From 3 Cohorts. American Journal of Epidemiology, 2015, 182, 187-197.	1.6	50
111	5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. JAMA Oncology, 2015, 1, 314.	3.4	32
112	A Prospective Study of Insulin-Like Growth Factor 1, Its Binding Protein 3, and Risk of Endometriosis. American Journal of Epidemiology, 2015, 182, 148-156.	1.6	14
113	Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncology, The, 2015, 16, 839-847.	5.1	321
114	Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. Breast Cancer Research and Treatment, 2015, 153, 353-360.	1.1	4
115	Prediagnostic plasma <scp>IGFBP</scp> â€1, <scp>IGF</scp> â€1 and risk of prostate cancer. International Journal of Cancer, 2015, 136, 2418-2426.	2.3	76
116	Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin. Molecular Cancer Therapeutics, 2014, 13, 399-409.	1.9	83
117	Insulin-like Growth Factor Pathway Genetic Polymorphisms, Circulating IGF1 and IGFBP3, and Prostate Cancer Survival. Journal of the National Cancer Institute, 2014, 106, dju085.	3.0	33
118	The Use of Metformin in Patients with Prostate Cancer and the Risk of Death. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2111-2118.	1.1	40
119	Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Research and Treatment, 2014, 148, 81-90.	1.1	65
120	Associations between time spent sitting and cancer-related biomarkers in postmenopausal women: an exploration of effect modifiers. Cancer Causes and Control, 2014, 25, 1427-1437.	0.8	8
121	Insulin-like Growth Factor Pathway Genetic Polymorphisms, Circulating IGF1 and IGFBP3, and Prostate Cancer Survival. Journal of the National Cancer Institute, 2014, 106, .	3.0	16
122	Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2014, 20, 1925-1934.	3.2	36
123	Risk of Breast Cancer by Individual Insulin Use: An International Multicenter Study. Diabetes Care, 2014, 37, 134-143.	4.3	18
124	Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Research, 2014, 16, R8.	2.2	31
125	Fasting insulin and endogenous hormones in relation to premenopausal breast density (Canada). Cancer Causes and Control, 2014, 25, 385-394.	0.8	12
126	Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes and Control, 2014, 25, 329-338.	0.8	56

#	Article	IF	CITATIONS
127	Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth. Molecular and Cellular Endocrinology, 2014, 384, 117-125.	1.6	16
128	Somatic point mutations occurring early in development: a monozygotic twin study. Journal of Medical Genetics, 2014, 51, 28-34.	1.5	73
129	Serine Deprivation Enhances Antineoplastic Activity of Biguanides. Cancer Research, 2014, 74, 7521-7533.	0.4	113
130	Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochemical Journal, 2014, 462, 475-487.	1.7	502
131	Metformin: From Mechanisms of Action to Therapies. Cell Metabolism, 2014, 20, 953-966.	7.2	1,019
132	Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecologic Oncology, 2014, 134, 607-614.	0.6	97
133	Quantification of Binding of IGF-1 to BI 836845, a Candidate Therapeutic Antibody Against IGF-1 and IGF-2, and Effects of This Antibody on IGF-1:IGFBP-3 Complexes In Vitro and in Male C57BL/6 Mice. Endocrinology, 2014, 155, 703-715.	1.4	18
134	Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer & Metabolism, 2014, 2, 12.	2.4	330
135	Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nature Medicine, 2014, 20, 1193-1198.	15.2	510
136	Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer. European Journal of Cancer, 2014, 50, 2838-2845.	1.3	32
137	Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study. Cancer Causes and Control, 2014, 25, 625-632.	0.8	27
138	Serum transforming growth factor-β1 and risk of pancreatic cancer in three prospective cohort studies. Cancer Causes and Control, 2014, 25, 1083-1091.	0.8	12
139	Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment. Nature Medicine, 2014, 20, 591-593.	15.2	95
140	Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09). European Urology, 2014, 66, 468-474.	0.9	100
141	Circulating IGF-axis protein levels and their relation with levels of plasma adipocytokines and macronutrient consumption in women. Growth Hormone and IGF Research, 2014, 24, 142-149.	0.5	3
142	Competing risks of death in younger and older postmenopausal breast cancer patients. World Journal of Clinical Oncology, 2014, 5, 1088.	0.9	13
143	Abstract 29: Design of a phase I chemoprevention study of metformin and Li-Fraumeni syndrome (LFS). , 2014, , .		1
144	Metformin improves healthspan and lifespan in mice. Nature Communications, 2013, 4, 2192.	5.8	1,118

#	Article	IF	CITATIONS
145	mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation. Cell Metabolism, 2013, 18, 698-711.	7.2	647
146	Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1984-1993.	1.1	41
147	Metformin Decreases Glucose Oxidation and Increases the Dependency of Prostate Cancer Cells on Reductive Glutamine Metabolism. Cancer Research, 2013, 73, 4429-4438.	0.4	178
148	Exercise Does Not Counteract the Effects of a "Westernized―Diet on Prostate Cancer Xenografts. Prostate, 2013, 73, 1223-1232.	1.2	8
149	The Use of Metformin and the Incidence of Lung Cancer in Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 124-129.	4.3	74
150	Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. Carcinogenesis, 2013, 34, 109-112.	1.3	42
151	Whole Milk Intake Is Associated with Prostate Cancer-Specific Mortality among U.S. Male Physicians. Journal of Nutrition, 2013, 143, 189-196.	1.3	82
152	Racial variation in vitamin D cord blood concentration in white and black male neonates. Cancer Causes and Control, 2013, 24, 91-98.	0.8	19
153	Plasma C-Peptide, Mammographic Breast Density, and Risk of Invasive Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1786-1796.	1.1	33
154	Targeting Oxidative Phosphorylation: Why, When, and How. Cancer Cell, 2013, 23, 263-264.	7.7	47
155	Metformin inhibits the senescenceâ€associated secretory phenotype by interfering with <scp>IKK</scp> / <scp>NF</scp> â€₽ <scp>B</scp> activation. Aging Cell, 2013, 12, 489-498.	3.0	422
156	IGF2 increases de novo steroidogenesis in prostate cancer cells. Endocrine-Related Cancer, 2013, 20, 173-186.	1.6	48
157	The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. Cell, 2013, 153, 1064-1079.	13.5	348
158	Serum leptin and adiponectin levels and risk of renal cell carcinoma. Obesity, 2013, 21, 1478-1485.	1.5	57
159	Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer. Cancer Causes and Control, 2013, 24, 839-845.	0.8	4
160	Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer. Genes and Cancer, 2013, 4, 535-545.	0.6	3
161	Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. Journal of the National Cancer Institute, 2013, 105, 1881-1890.	3.0	80
162	Hyperglycemia, Insulin Resistance, Impaired Pancreatic β-Cell Function, and Risk of Pancreatic Cancer. Journal of the National Cancer Institute, 2013, 105, 1027-1035.	3.0	146

#	Article	IF	CITATIONS
163	Inflammatory Plasma Markers and Pancreatic Cancer Risk: A Prospective Study of Five U.S. Cohorts. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 855-861.	1.1	28
164	Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case–control study within the Bâ^¼FIT cohort. Endocrine-Related Cancer, 2013, 20, 151-160.	1.6	48
165	Insulin-Like Growth Factors and Insulin-Like Growth Factor–Binding Proteins and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Cancer Prevention Research, 2013, 6, 91-99.	0.7	28
166	The Use of Metformin and Colorectal Cancer Incidence in Patients with Type II Diabetes Mellitus. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1877-1883.	1.1	55
167	A Prospective Study of Plasma Adiponectin and Pancreatic Cancer Risk in Five US Cohorts. Journal of the National Cancer Institute, 2013, 105, 95-103.	3.0	101
168	Systemic cancer therapy: achievements and challenges that lie ahead. Frontiers in Pharmacology, 2013, 4, 57.	1.6	165
169	Potential applications for biguanides in oncology. Journal of Clinical Investigation, 2013, 123, 3693-3700.	3.9	162
170	Aspirin use in prostate cancer and the risk of death and metastasis Journal of Clinical Oncology, 2013, 31, 1518-1518.	0.8	1
171	Treatment with Insulin Analog X10 and IGF-1 Increases Growth of Colon Cancer Allografts. PLoS ONE, 2013, 8, e79710.	1.1	29
172	Metformin, aging and cancer. Aging, 2013, 5, 330-331.	1.4	41
173	Individual insulin use and the risk of breast cancer: An international clinical epidemiology study Journal of Clinical Oncology, 2013, 31, 1578-1578.	0.8	0
174	Metformin and biomarkers relevant to neoplasia in nondiabetic patients Journal of Clinical Oncology, 2013, 31, e14615-e14615.	0.8	2
175	Final results of a phase II study of neoadjuvant metformin in prostatic carcinoma Journal of Clinical Oncology, 2013, 31, 5070-5070.	0.8	0
176	Genetic Variants, Prediagnostic Circulating Levels of Insulin-like Growth Factors, Insulin, and Glucose and the Risk of Colorectal Cancer: The Multiethnic Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 810-820.	1.1	39
177	Metformin and Hepatic Carcinogenesis. Cancer Prevention Research, 2012, 5, 500-502.	0.7	9
178	Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. Journal of Applied Physiology, 2012, 113, 263-272.	1.2	98
179	A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer. Clinical Cancer Research, 2012, 18, 3407-3413.	3.2	47
180	Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study. European Journal of Clinical Nutrition, 2012, 66, 1146-1152.	1.3	42

#	Article	IF	CITATIONS
181	Decline in Circulating Insulin-Like Growth Factors and Mortality in Older Adults: Cardiovascular Health Study All-Stars Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1970-1976.	1.8	22
182	The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ, The, 2012, 344, e3645-e3645.	3.0	237
183	A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation. Oncogene, 2012, 31, 1334-1340.	2.6	19
184	Magnesium intake, plasma C-peptide, and colorectal cancer incidence in US women: a 28-year follow-up study. British Journal of Cancer, 2012, 106, 1335-1341.	2.9	18
185	The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology. Clinical Cancer Research, 2012, 18, 40-50.	3.2	89
186	Reply to P. Ameri et al. Journal of Clinical Oncology, 2012, 30, 1396-1396.	0.8	0
187	The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer. Advances in Urology, 2012, 2012, 1-11.	0.6	24
188	Metformin and Pancreatic Cancer: A Clue Requiring Investigation. Clinical Cancer Research, 2012, 18, 2723-2725.	3.2	31
189	Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood, 2012, 120, 4929-4937.	0.6	41
190	A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood, 2012, 120, 4418-4420.	0.6	58
191	Carbon Source and Myc Expression Influence the Antiproliferative Actions of Metformin. Cancer Research, 2012, 72, 6257-6267.	0.4	39
192	Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and lobule type in the Nurses' Health Study II. Breast Cancer Research, 2012, 14, R44.	2.2	16
193	Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses' Health Studies. Breast Cancer Research and Treatment, 2012, 136, 805-812.	1.1	29
194	Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies. Cancer Causes and Control, 2012, 23, 779-784.	0.8	18
195	IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein. Experimental Hematology, 2012, 40, 715-723.e6.	0.2	20
196	Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning. Cancer Discovery, 2012, 2, 778-790.	7.7	443
197	Metformin Reduces Endogenous Reactive Oxygen Species and Associated DNA Damage. Cancer Prevention Research, 2012, 5, 536-543.	0.7	284
198	Insulin-Like Growth Factor Axis and Risk of Type 2 Diabetes in Women. Diabetes, 2012, 61, 2248-2254.	0.3	116

#	Article	IF	CITATIONS
199	IGFBP7 Binds to the IGF-1 Receptor and Blocks Its Activation by Insulin-Like Growth Factors. Science Signaling, 2012, 5, ra92.	1.6	123
200	Alterations in Cellular Energy Metabolism Associated with the Antiproliferative Effects of the ATM Inhibitor KU-55933 and with Metformin. PLoS ONE, 2012, 7, e49513.	1.1	29
201	Distinct perturbation of the translatome by the antidiabetic drug metformin. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8977-8982.	3.3	169
202	Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. International Journal of Cancer, 2012, 131, E105-13.	2.3	51
203	Stimulation of MC38 tumor growth by insulin analog X10 involves the serine synthesis pathway. Endocrine-Related Cancer, 2012, 19, 557-574.	1.6	10
204	A dietary pattern that is associated with C-peptide and risk of colorectal cancer in women. Cancer Causes and Control, 2012, 23, 959-965.	0.8	35
205	The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nature Reviews Cancer, 2012, 12, 159-169.	12.8	929
206	Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Research and Treatment, 2012, 132, 131-142.	1.1	117
207	Racial variation in umbilical cord blood sex steroid hormones and the insulin-like growth factor axis in African-American and white female neonates. Cancer Causes and Control, 2012, 23, 445-454.	0.8	10
208	Abstract CT-04: A phase II study of neoadjuvant metformin in prostatic carcinoma. , 2012, , .		2
209	Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29 Journal of Clinical Oncology, 2012, 30, 538-538.	0.8	0
210	Assessment of the prognostic and predictive utility of the breast cancer index (BCI): An NCIC CTG MA.14 study Journal of Clinical Oncology, 2012, 30, 561-561.	0.8	0
211	A phase II trial of neoadjuvant metformin in prostatic adenocarcinoma with serum and tissue biomarker evaluation Journal of Clinical Oncology, 2012, 30, e15118-e15118.	0.8	0
212	Dual effectsÂof metformin on breast cancer proliferation in a randomizedÂtrial Journal of Clinical Oncology, 2012, 30, 519-519.	0.8	6
213	Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. Biochemical and Biophysical Research Communications, 2011, 414, 694-699.	1.0	80
214	Interactions between Plasma Levels of 25-Hydroxyvitamin D, Insulin-Like Growth Factor (IGF)-1 and C-Peptide with Risk of Colorectal Cancer. PLoS ONE, 2011, 6, e28520.	1.1	32
215	Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene, 2011, 30, 1174-1182.	2.6	161
216	Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. British Journal of Cancer, 2011, 104, 68-74.	2.9	79

#	Article	IF	CITATIONS
217	Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins. Gynecologic Oncology, 2011, 121, 492-498.	0.6	113
218	Body Size in Early Life and Adult Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3. American Journal of Epidemiology, 2011, 174, 642-651.	1.6	62
219	Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis. Cancer Causes and Control, 2011, 22, 1587-1595.	0.8	18
220	A prospective study of intakes of zinc and heme iron and colorectal cancer risk in men and women. Cancer Causes and Control, 2011, 22, 1627-1637.	0.8	46
221	Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia, 2011, 54, 2254-2262.	2.9	93
222	Human prostate cancer xenografts in <i>lit/lit</i> mice exhibit reduced growth and and rogenâ€independent progression. Prostate, 2011, 71, 525-537.	1.2	19
223	Diabetes and breast cancer among women with <i>BRCA1</i> and <i>BRCA2</i> mutations. Cancer, 2011, 117, 1812-1818.	2.0	62
224	Plasma insulinâ€like growth factor 1 is positively associated with lowâ€grade prostate cancer in the Health Professionals Followâ€up Study 1993–2004. International Journal of Cancer, 2011, 128, 660-667.	2.3	31
225	A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. Human Molecular Genetics, 2011, 20, 1241-1251.	1.4	67
226	Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 337-344.	1.1	120
227	Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2618-2627.	1.1	50
228	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. Journal of Experimental Medicine, 2011, 208, 1809-1822.	4.2	153
229	Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14. Journal of Clinical Oncology, 2011, 29, 3605-3610.	0.8	57
230	Serum C-Reactive Protein and Risk of Pancreatic Cancer in Two Nested, Case–Control Studies. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 359-369.	1.1	26
231	Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c. Clinical Cancer Research, 2011, 17, 5765-5773.	3.2	120
232	Metformin abolishes increased tumor18F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet. Cell Cycle, 2011, 10, 2770-2778.	1.3	38
233	ETV6-NTRK3–Mediated Breast Epithelial Cell Transformation Is Blocked by Targeting the IGF1R Signaling Pathway. Cancer Research, 2011, 71, 1060-1070.	0.4	61
234	Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14. Journal of Clinical Oncology, 2011, 29, 3869-3876.	0.8	83

#	Article	IF	CITATIONS
235	Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741. Journal of Clinical Oncology, 2011, 29, 1599-1606.	0.8	85
236	IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. Endocrine-Related Cancer, 2011, 18, 699-709.	1.6	31
237	Insulin Increases <i>De Novo</i> Steroidogenesis in Prostate Cancer Cells. Cancer Research, 2011, 71, 5754-5764.	0.4	97
238	Reply: â€~Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab'. British Journal of Cancer, 2011, 105, 1467-1467.	2.9	1
239	Binding between Insulin-like Growth Factor 1 and Insulin-like Growth Factor-binding Protein 3 Is Not Influenced by Glucose or 2-Deoxy-d-glucose. Journal of Biological Chemistry, 2011, 286, 16567-16573.	1.6	10
240	Metformin Abolishes Increased Tumor FDG Uptake Associated With a Highâ€Energy Diet. FASEB Journal, 2011, 25, lb314.	0.2	0
241	Low vs. high glycemic load diets reduce insulinâ€like growth factors and inflammatory factors in overweight persons in a controlled feeding study. FASEB Journal, 2011, 25, 94.7.	0.2	0
242	Binding between IGFâ€1 and IGFBPâ€3 is not influenced by glucose or 2â€DG. FASEB Journal, 2011, 25, lb135.	0.2	0
243	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. Journal of Cell Biology, 2011, 194, i8-i8.	2.3	0
244	Synthetic Lethality Screens Reveal RPS6 and MST1R as Modifiers of Insulin-like Growth Factor-1 Receptor Inhibitor Activity in Childhood Sarcomas. Cancer Research, 2010, 70, 8770-8781.	0.4	58
245	Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. Diabetologia, 2010, 53, 2086-2088.	2.9	35
246	Circulating Insulin-like Growth Factor (IGF)-I and IGF Binding Protein (IGFBP)-3 Levels and Postmenopausal Breast Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort. Hormones and Cancer, 2010, 1, 100-111.	4.9	19
247	Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. Breast Cancer Research and Treatment, 2010, 122, 647-659.	1.1	37
248	Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Research and Treatment, 2010, 123, 271-279.	1.1	179
249	Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes and Control, 2010, 21, 1-10.	0.8	59
250	Diabetes and Cancer: A Consensus Report. Ca-A Cancer Journal for Clinicians, 2010, 60, 207-221.	157.7	724
251	Genetic variation and circulating levels of IGFâ€I and IGFBPâ€3 in relation to risk of proliferative benign breast disease. International Journal of Cancer, 2010, 126, 180-190.	2.3	45
252	A study of highâ€dose oral silybinâ€phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate, 2010, 70, 848-855.	1.2	141

#	Article	IF	CITATIONS
253	Androgens, growth factors, and risk of prostate cancer: The Multiethnic Cohort. Prostate, 2010, 70, 906-915.	1.2	33
254	Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man. Prostate, 2010, 70, 1628-1635.	1.2	23
255	Insulin analogues and cancer risk: cause for concern orcause célà bre?. International Journal of Clinical Practice, 2010, 64, 628-636.	0.8	43
256	Insulin-like growth factors and risk of kidney cancer in men. British Journal of Cancer, 2010, 103, 132-135.	2.9	26
257	Insulin-like growth factors and liver cancer risk in male smokers. British Journal of Cancer, 2010, 103, 1089-1092.	2.9	10
258	Plasma Levels of Acid-Labile Subunit, Free Insulin-Like Growth Factor-I, and Prostate Cancer Risk: A Prospective Study. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 484-491.	1.1	16
259	elF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14134-14139.	3.3	447
260	Finasteride Modifies the Relation between Serum C-Peptide and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Cancer Prevention Research, 2010, 3, 279-289.	0.7	33
261	Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortiumâ€. Human Molecular Genetics, 2010, 19, 3873-3884.	1.4	45
262	Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 Molar Ratio and Risk of Pancreatic Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2298-2306.	1.1	69
263	A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians â€. Human Molecular Genetics, 2010, 19, 3089-3101.	1.4	47
264	Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. Prostate Cancer and Prostatic Diseases, 2010, 13, 350-355.	2.0	45
265	Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocrine-Related Cancer, 2010, 17, 351-360.	1.6	203
266	Diabetes and Cancer. Diabetes Care, 2010, 33, 1674-1685.	4.3	1,618
267	Fasting Plasma Insulin, C-Peptide and Cognitive Change in Older Men without Diabetes: Results from the Physicians' Health Study II. Neuroepidemiology, 2010, 34, 200-207.	1.1	25
268	IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors, 2010, 28, 243-255.	0.5	46
269	Effect of Isocaloric Low Fat Diet on Prostate Cancer Xenograft Progression in a Hormone Deprivation Model. Journal of Urology, 2010, 183, 1619-1624.	0.2	14
270	Metformin and Other Biguanides in Oncology: Advancing the Research Agenda. Cancer Prevention Research, 2010, 3, 1060-1065.	0.7	205

#	Article	IF	CITATIONS
271	Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose. Cancer Letters, 2010, 289, 246-253.	3.2	27
272	Protective effect of metformin in CD1 mice placed on a high carbohydrate–high fat diet. Biochemical and Biophysical Research Communications, 2010, 397, 537-542.	1.0	40
273	Beyond steroid hormones: the new cancer endocrinology. Lancet Oncology, The, 2010, 11, 501-502.	5.1	1
274	Insights into the pharmacologic inhibition of insulin receptor tyrosine kinase in cancer: avoiding severe metabolic toxicity. FASEB Journal, 2010, 24, lb442.	0.2	0
275	The Effects of Varying Dietary Carbohydrate and Fat Content on Survival in a Murine LNCaP Prostate Cancer Xenograft Model. Cancer Prevention Research, 2009, 2, 557-565.	0.7	98
276	Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma. Cancer Research, 2009, 69, 2443-2452.	0.4	96
277	Insulin-Like Growth Factors and Leukocyte Telomere Length: The Cardiovascular Health Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 1103-1106.	1.7	23
278	Racial Variation in Sex Steroid Hormones and the Insulin-Like Growth Factor Axis in Umbilical Cord Blood of Male Neonates. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1484-1491.	1.1	40
279	Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 176-185.	0.8	208
280	Macronutrient Intake and Cancer: How Does Dietary Restriction Influence Tumor Growth and Why Should We Care?. Cancer Prevention Research, 2009, 2, 698-701.	0.7	6
281	Higher circulating levels of IGF-1 are associated with longer leukocyte telomere length in healthy subjects. Mechanisms of Ageing and Development, 2009, 130, 771-776.	2.2	54
282	BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecologic Oncology, 2009, 115, 193-198.	0.6	28
283	A profile of impaired insulin degradation in relation to lateâ€life cognitive decline: A preliminary investigation. International Journal of Geriatric Psychiatry, 2009, 24, 177-182.	1.3	18
284	Insulin receptor expression by human prostate cancers. Prostate, 2009, 69, 33-40.	1.2	203
285	Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene, 2009, 28, 3009-3021.	2.6	265
286	Aging, IGFâ€1, and diet. Aging Cell, 2009, 8, 214-214.	3.0	1
287	Do Cancer Cells Care If Their Host Is Hungry?. Cell Metabolism, 2009, 9, 401-403.	7.2	34
288	Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. American Journal of Clinical Nutrition, 2009, 89, 634-640.	2.2	214

#	ARTICLE	IF	CITATIONS
289	Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy. BioDrugs, 2009, 23, 77-91.	2.2	45
290	Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin. Journal of Thoracic Oncology, 2009, 4, 1397-1403.	0.5	62
291	Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology. Current Drug Targets, 2009, 10, 923-936.	1.0	55
292	Energy Metabolism, Cancer Risk, and Cancer Prevention. Recent Results in Cancer Research, 2009, 181, 51-54.	1.8	8
293	Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes and Control, 2008, 19, 703-710.	0.8	47
294	Insulinâ€like growth factorâ€l, insulinâ€like growth factor binding proteinâ€3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate, 2008, 68, 1477-1486.	1.2	54
295	Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer, 2008, 8, 915-928.	12.8	1,792
296	Total Insulinlike Growth Factor 1 and Insulinlike Growth Factor Binding Protein Levels, Functional Status, and Mortality in Older Adults. Journal of the American Geriatrics Society, 2008, 56, 652-660.	1.3	48
297	In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecologic Oncology, 2008, 110, 246-250.	0.6	249
298	Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes. Psychoneuroendocrinology, 2008, 33, 455-461.	1.3	24
299	Insulin, insulin-like growth factors and neoplasia. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 625-638.	2.2	85
300	Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Research, 2008, 10, R86.	2.2	107
301	Intact and total insulin-like growth factor-binding protein-3 (IGFBP-3) levels in relation to breast cancer risk factors: a cross-sectional study. Breast Cancer Research, 2008, 10, R42.	2.2	12
302	High insulinlike growth factor binding protein 1 level predicts incident congestive heart failure in the elderly. American Heart Journal, 2008, 155, 1006-1012.	1.2	30
303	Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Hormone and IGF Research, 2008, 18, 166-173.	0.5	65
304	Targeting insulin and insulin-like growth factor signalling in oncology. Current Opinion in Pharmacology, 2008, 8, 384-392.	1.7	90
305	Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncology, The, 2008, 9, 1039-1047.	5.1	385
306	Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival. Cancer Research, 2008, 68, 10238-10246.	0.4	364

#	Article	IF	CITATIONS
307	Prediagnostic Adiponectin Concentrations and Pancreatic Cancer Risk in Male Smokers. American Journal of Epidemiology, 2008, 168, 1047-1055.	1.6	70
308	The Type 1 Insulin-Like Growth Factor Receptor Pathway. Clinical Cancer Research, 2008, 14, 6364-6370.	3.2	387
309	The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase. Cancer Prevention Research, 2008, 1, 369-375.	0.7	266
310	Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocrine-Related Cancer, 2008, 15, 833-839.	1.6	165
311	Vitamin D Pathway Polymorphisms in Relation to Mammographic Breast Density. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2505-2508.	1.1	7
312	IGF-I, IGFBP-3, and IGF-I/IGFBP-3 Ratio: No Association with Incident Colorectal Cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1832-1834.	1.1	14
313	Fasting Insulin Levels and Cognitive Decline in Older Women without Diabetes. Neuroepidemiology, 2008, 30, 174-179.	1.1	41
314	Genetic Polymorphisms Involved in Insulin-like Growth Factor (IGF) Pathway in Relation to Mammographic Breast Density and IGF Levels. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 880-888.	1.1	58
315	Plasma Insulinlike Growth Factor 1 and Binding-Protein 3 and Risk of Myocardial Infarction in Women: A Prospective Study. Clinical Chemistry, 2008, 54, 1682-1688.	1.5	21
316	Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer. Clinical Cancer Research, 2008, 14, 6944-6954.	3.2	71
317	A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 921-929.	1.1	224
318	Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741. Clinical Cancer Research, 2008, 14, 8263-8269.	3.2	52
319	Prostate Cancer Risk in Relation to Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3: A Prospective Multiethnic Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 252-254.	1.1	26
320	Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 3196-3203.	0.8	152
321	IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE, 2008, 3, e2578.	1.1	106
322	Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies. Annals of Internal Medicine, 2008, 149, 461.	2.0	263
323	Insulin-Like Growth Factors and Neoplasia. Novartis Foundation Symposium, 2008, , 84-107.	1.2	61
324	IGF Signaling Is Critical for Growth and Survival of T-Cell Acute Lymphoblastic Leukemia Cells and Is Potentiated by Notch Upregulation of IGF1R. Blood, 2008, 112, 3811-3811.	0.6	1

#	Article	IF	CITATIONS
325	Prediagnostic C-Peptide and Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2164-2165.	1.1	18
326	Dietary Feeding of Silibinin Inhibits Prostate Tumor Growth and Progression in Transgenic Adenocarcinoma of the Mouse Prostate Model. Cancer Research, 2007, 67, 11083-11091.	0.4	71
327	Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis, 2007, 28, 2567-2574.	1.3	68
328	Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. British Journal of Cancer, 2007, 97, 98-104.	2.9	60
329	Insulin-like Growth Factor-I and Risk of High-Grade Cervical Intraepithelial Neoplasia. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 716-722.	1.1	24
330	Association of Diet-Induced Hyperinsulinemia With Accelerated Growth of Prostate Cancer (LNCaP) Xenografts. Journal of the National Cancer Institute, 2007, 99, 1793-1800.	3.0	160
331	C-Reactive Protein Concentrations and Subsequent Ovarian Cancer Risk. Obstetrics and Gynecology, 2007, 109, 933-941.	1.2	80
332	Association of Total Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1), and IGFBP-3 Levels with Incident Coronary Events and Ischemic Stroke. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1319-1325.	1.8	110
333	Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor. Clinical Cancer Research, 2007, 13, 3611-3616.	3.2	185
334	Prediagnostic Plasma C-Peptide and Pancreatic Cancer Risk in Men and Women. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2101-2109.	1.1	93
335	Body shape throughout life and correlations with IGFs and GH. Endocrine-Related Cancer, 2007, 14, 721-732.	1.6	62
336	Synchronized Seasonal Variations of Mammographic Breast Density and Plasma 25-Hydroxyvitamin D. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 929-933.	1.1	49
337	Metformin Inhibits Mammalian Target of Rapamycin–Dependent Translation Initiation in Breast Cancer Cells. Cancer Research, 2007, 67, 10804-10812.	0.4	845
338	Insulin-like Growth Factors and Ovarian Cancer Risk: A Nested Case-Control Study in Three Cohorts. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1691-1695.	1.1	37
339	Circulating Insulin-Like Growth Factor Binding Protein-1 and the Risk of Pancreatic Cancer. Cancer Research, 2007, 67, 7923-7928.	0.4	71
340	Circulating Insulin and C-Peptide Levels and Risk of Breast Cancer among Predominately Premenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 161-164.	1.1	67
341	Glioma Risk in Relation to Serum Levels of Insulin-Like Growth Factors. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 844-846.	1.1	24
342	Insulin, insulin-like growth factors, insulin resistance, and neoplasia. American Journal of Clinical Nutrition, 2007, 86, 820S-822S.	2.2	64

#	Article	IF	CITATIONS
343	Plasma IGF-I levels and cognitive performance in older women. Neurobiology of Aging, 2007, 28, 135-142.	1.5	56
344	The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cancer Letters, 2007, 255, 300-306.	3.2	29
345	Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Research, 2007, 9, R18.	2.2	65
346	Milk consumption and the prepubertal somatotropic axis. Nutrition Journal, 2007, 6, 28.	1.5	103
347	Hypoxia-inducible factor-1α (HIF-1α) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate, 2007, 67, 1354-1361.	1.2	49
348	Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene, 2007, 26, 1811-1819.	2.6	93
349	Insulin-Like Growth Factor-Related Signaling and Cancer Development. , 2007, 174, 49-53.		54
350	Metformin Is an AMP Kinase–Dependent Growth Inhibitor for Breast Cancer Cells. Cancer Research, 2006, 66, 10269-10273.	0.4	972
351	Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). Growth Hormone and IGF Research, 2006, 16, 86-92.	0.5	21
352	Relation of insulin-like growth factor (IGF) I and IGF-binding protein 3 concentrations with intakes of fruit, vegetables, and antioxidants. American Journal of Clinical Nutrition, 2006, 84, 1518-1526.	2.2	21
353	Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecologic Oncology, 2006, 100, 389-396.	0.6	66
354	Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. International Journal of Cancer, 2006, 118, 1279-1284.	2.3	32
355	Diabetes mellitus and cancer risk in a population-based case-controlstudy among men from Montreal, Canada. International Journal of Cancer, 2006, 118, 2105-2109.	2.3	126
356	Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocrine-Related Cancer, 2006, 13, 583-592.	1.6	120
357	Influence of Insulin-like Growth Factors on the Strength of the Relation of Vitamin D and Calcium Intakes to Mammographic Breast Density. Cancer Research, 2006, 66, 588-597.	0.4	55
358	Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1977-1983.	1.1	300
359	C-Peptide, Insulin-like Growth Factor Binding Protein-1, Glycosylated Hemoglobin, and the Risk of Distal Colorectal Adenoma in Women. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 750-755.	1.1	73
360	Reproducibility of Plasma Steroid Hormones, Prolactin, and Insulin-like Growth Factor Levels among Premenopausal Women over a 2- to 3-Year Period. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 972-978.	1.1	118

#	Article	IF	CITATIONS
361	No Association between Serum Insulin-Like Growth Factor (IGF)-I, IGF-Binding Protein-3, and Lung Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2010-2012.	1.1	15
362	Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor. Molecular Pharmacology, 2006, 70, 1534-1541.	1.0	74
363	A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene, 2005, 24, 4736-4740.	2.6	58
364	Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene, 2005, 24, 4281-4292.	2.6	251
365	Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes and Control, 2005, 16, 255-262.	0.8	65
366	Individualizing Interventions for Cancer Prevention. , 2005, 166, 63-70.		0
367	Levels of C-Peptide and Mammographic Breast Density. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2661-2664.	1.1	17
368	Centralized Blood Processing for the Selenium and Vitamin E Cancer Prevention Trial: Effects of Delayed Processing on Carotenoids, Tocopherols, Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein 3, Steroid Hormones, and Lymphocyte Viability. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 727-730.	1.1	26
369	A Prospective Study of C-Peptide, Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-1, and the Risk of Colorectal Cancer in Women. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 850-855.	1.1	206
370	Racial Differences in Premenopausal Endogenous Hormones. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2147-2153.	1.1	100
371	Vitamin D and Calcium Intakes from Food or Supplements and Mammographic Breast Density. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1653-1659.	1.1	91
372	Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1402-1410.	1.1	18
373	Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group. Journal of Clinical Oncology, 2005, 23, 455-460.	0.8	195
374	Serum Insulin-Like Growth Factor-I Levels and Prostatic Intraepithelial Neoplasia: A Clue to the Relationship Between IGF-I Physiology and Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1270-1273.	1.1	28
375	Circulating Levels of Insulin-like Growth Factors, their Binding Proteins, and Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 699-704.	1.1	164
376	Insulin-Like Growth Factor-I, IGF-Binding Protein-3, and Mammographic Breast Density. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1065-1073.	1.1	134
377	PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochemical and Biophysical Research Communications, 2005, 336, 1056-1061.	1.0	51
378	Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Research, 2005, 7, R796-807.	2.2	83

#	Article	IF	CITATIONS
379	Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Research, 2005, 7, R570-9.	2.2	112
380	Activity and Safety of the Antiestrogen EM-800, the Orally Active Precursor of Acolbifene, in Tamoxifen-Resistant Breast Cancer. Journal of Clinical Oncology, 2004, 22, 864-871.	0.8	42
381	A Prospective Study of Plasma C-Peptide and Colorectal Cancer Risk in Men. Journal of the National Cancer Institute, 2004, 96, 546-553.	3.0	311
382	Insulin-like growth factors and neoplasia. Nature Reviews Cancer, 2004, 4, 505-518.	12.8	1,422
383	Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. British Journal of Cancer, 2004, 90, 1825-1829.	2.9	45
384	Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. International Journal of Cancer, 2004, 108, 334-341.	2.3	193
385	Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. International Journal of Cancer, 2004, 108, 773-779.	2.3	81
386	Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc–MAPK signaling pathway in breast cancer cells. Biochemical and Biophysical Research Communications, 2004, 313, 709-715.	1.0	30
387	Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochemical and Biophysical Research Communications, 2004, 316, 421-428.	1.0	30
388	Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 438-44.	1.1	22
389	A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 573-82.	1.1	22
390	Insulin-like growth factors and neoplasia. Novartis Foundation Symposium, 2004, 262, 84-98; discussion 98-107, 265-8.	1.2	37
391	Polymorphic variation at the -202 locus inIGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. International Journal of Cancer, 2003, 107, 60-64.	2.3	75
392	Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples. BJU International, 2003, 92, 699-702.	1.3	14
393	Challenges to cancer control by screening. Nature Reviews Cancer, 2003, 3, 297-303.	12.8	28
394	Serum Insulin-like Growth Factor I and Subsequent Risk of Colorectal Cancer among Japanese-American Men. American Journal of Epidemiology, 2003, 158, 424-431.	1.6	46
395	Re: Italian Randomized Trial Among Women With Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High-Risk Women. Journal of the National Cancer Institute, 2003, 95, 917-917.	3.0	0
396	Soy Isoflavones in the Treatment of Prostate Cancer. Nutrition and Cancer, 2003, 47, 111-117.	0.9	150

#	Article	IF	CITATIONS
397	Mammary-specific deletion of parathyroid hormone–related protein preserves bone mass during lactation. Journal of Clinical Investigation, 2003, 112, 1429-1436.	3.9	156
398	Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 84-9.	1.1	112
399	Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 412-8.	1.1	76
400	Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Research, 2003, 63, 3991-4.	0.4	94
401	Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 1429-37.	1.1	29
402	Insulin-Like Growth Factor-I (IGF-I) and IGF Binding Protein-3 as Predictors of Advanced-Stage Prostate Cancer. Journal of the National Cancer Institute, 2002, 94, 1099-1106.	3.0	377
403	Lycopene in the treatment of prostate cancer. Pure and Applied Chemistry, 2002, 74, 1443-1450.	0.9	23
404	Effects of Lycopene Supplementation in Patients with Localized Prostate Cancer. Experimental Biology and Medicine, 2002, 227, 881-885.	1.1	162
405	Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-3 for Prostate Cancer Detection in Patients Undergoing Prostate Biopsy. Journal of Urology, 2002, 168, 2426-2430.	0.2	22
406	Risk of cancer after growth-hormone treatment. Lancet, The, 2002, 360, 268-269.	6.3	18
407	Reduced growth of human sarcoma xenografts in hosts homozygous for thelit mutation. Journal of Surgical Oncology, 2002, 81, 75-79.	0.8	29
408	A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. International Journal of Cancer, 2002, 100, 332-336.	2.3	84
409	Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 852-61.	1.1	126
410	Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 862-7.	1.1	55
411	Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1413-8.	1.1	32
412	Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Research, 2002, 62, 7372-6.	0.4	33
413	Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Medical Science Monitor, 2002, 8, BR521-6.	0.5	71
414	Serum insulin-like growth factor-I (IGF-I) does not correlate positively with isometric strength, fatigue, and quality of life in post-polio syndrome. Journal of the Neurological Sciences, 2001, 182, 107-115.	0.3	19

#	Article	IF	CITATIONS
415	Genetic Factors Related to Racial Variation in Plasma Levels of Insulin-Like Growth Factor-1: Implications for Premenopausal Breast Cancer Risk. Molecular Genetics and Metabolism, 2001, 72, 144-154.	0.5	101
416	Other novel agents: Rationale and current status as chemopreventive agents. Urology, 2001, 57, 86-89.	0.5	14
417	Insulin-like Growth Factors and Prostate Cancer. Epidemiologic Reviews, 2001, 23, 59-66.	1.3	82
418	Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. British Journal of Cancer, 2001, 85, 428-430.	2.9	114
419	Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin). Journal of the National Cancer Institute, 2001, 93, 1852-1857.	3.0	815
420	Milk Intake, Circulating Levels of Insulin-Like Growth Factor-I, and Risk of Colorectal Cancer in Men. Journal of the National Cancer Institute, 2001, 93, 1330-1336.	3.0	168
421	Tissue-Specific Targeting of the Pthrp Gene: The Generation of Mice with Floxed Alleles*. Endocrinology, 2001, 142, 2070-2077.	1.4	32
422	Novel Promoter Polymorphism in Insulin-Like Growth Factor-Binding Protein-3: Correlation with Serum Levels and Interaction with Known Regulators1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1274-1280.	1.8	178
423	Novel Promoter Polymorphism in Insulin-Like Growth Factor-Binding Protein-3: Correlation with Serum Levels and Interaction with Known Regulators. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1274-1280.	1.8	154
424	H19sense and antisense transgenes modify insulin-like growth factor-II mRNA levels. FEBS Journal, 2000, 267, 4020-4027.	0.2	46
425	Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Annals of Oncology, 2000, 11, 307-314.	0.6	76
426	Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial. Journal of Clinical Oncology, 2000, 18, 3758-3767.	0.8	973
427	Vertex balding, plasma insulin-like growth factor 1, and insulin-like growth factor binding protein 3. Journal of the American Academy of Dermatology, 2000, 42, 1003-1007.	0.6	24
428	The question of a link between insulin-like growth factor physiology and neoplasia. Growth Hormone and IGF Research, 2000, 10, S21-S24.	0.5	13
429	First International Workshop on Growth Hormone, Insulin-like Growth Factors and Neoplasia. Growth Hormone and IGF Research, 2000, 10, S1-S3.	0.5	9
430	Insulin-like growth factor physiology and neoplasia. Growth Hormone and IGF Research, 2000, 10, S6-S7.	0.5	21
431	Insulin-like growth factors and mammographic density. Growth Hormone and IGF Research, 2000, 10, S24-S25.	0.5	11
432	A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Hormone and IGF Research, 2000, 10, S28-S29.	0.5	69

#	Article	IF	CITATIONS
433	Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses' Health Study. Growth Hormone and IGF Research, 2000, 10, S30-S31.	0.5	45
434	Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies. Growth Hormone and IGF Research, 2000, 10, S32-S33.	0.5	39
435	Insulin-like growth factor physiology and cancer risk. European Journal of Cancer, 2000, 36, 1224-1228.	1.3	267
436	Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3. Journal of the National Cancer Institute, 1999, 91, 620-625.	3.0	1,022
437	Fatty acid metabolism in human breast cancer cells (MCF7) transfected with heart-type fatty acid binding protein. Molecular and Cellular Biochemistry, 1999, 199, 41-48.	1.4	18
438	A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. , 1999, 85, 1284-1292.		55
439	Circulating IGF-I: New Perspectives for a New Century. Trends in Endocrinology and Metabolism, 1999, 10, 136-141.	3.1	128
440	Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Urology, 1999, 54, 1120-1125.	0.5	39
441	Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Research and Treatment, 1998, 47, 209-217.	1.1	100
442	Insulin-like growth factors and prostate cancer. Cancer and Metastasis Reviews, 1998, 17, 383-390.	2.7	142
443	Cancer controversy. Nature, 1998, 392, 752-752.	13.7	1
444	Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. , 1998, 69, 21-27.		94
445	Insulin-like growth factor-l and risk of breast cancer. Lancet, The, 1998, 352, 489.	6.3	3
446	Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet, The, 1998, 351, 1393-1396.	6.3	1,706
447	I.4 Effects of anti-oestrogens on insulin-like growth factor (IGF-I) physiology systemically and in the uterus. European Journal of Cancer, 1998, 34, S11-S12.	1.3	1
448	Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study. Science, 1998, 279, 563-566.	6.0	1,872
449	Mechanisms of Antineoplastic Action of Somatostatin Analogs. Experimental Biology and Medicine, 1998, 217, 143-152.	1.1	134
450	Castration-Induced Apoptosis in the Rat Ventral Prostate Is Associated with Increased Expression of Genes Encoding Insulin-Like Growth Factor Binding Proteins 2, 3, 4 and 5. Endocrinology, 1998, 139, 807-810.	1.4	110

#	Article	IF	CITATIONS
451	Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. , 1998, 69, 21.		2
452	IGF-I Physiology and Breast Cancer. Recent Results in Cancer Research, 1998, 152, 63-70.	1.8	29
453	Overexpression of insulin-like growth factor binding protein 4 (IGFBP-4) in MCF-7 breast cancer cells is associated with reduced responsiveness to insulin-like growth factors in vitro and reduced tumour growth in vivo. International Journal of Oncology, 1997, 11, 193-7.	1.4	1
454	Antiproliferative Action of Vitamin D-Related Compounds and Insulin-Like Growth Factor-Binding Protein 5 Accumulation. Journal of the National Cancer Institute, 1997, 89, 652-656.	3.0	88
455	Insulin-like Growth Factor Binding Protein-3 Induces Apoptosis in MCF7 Breast Cancer Cells. Biochemical and Biophysical Research Communications, 1997, 237, 690-693.	1.0	145
456	Insulin-like Growth Factor Binding Protein-3 Induces Apoptosis in MCF7 Breast-Cancer Cells. Biochemical and Biophysical Research Communications, 1997, 240, 246.	1.0	0
457	Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer, 1997, 80, 435-441.	2.0	162
458	The Human Mammary-Derived Growth Inhibitor (MDGI) Gene: Genomic Structure and Mutation Analysis in Human Breast Tumors. Genomics, 1996, 34, 63-68.	1.3	31
459	The Human Mammary-Derived Growth Inhibitor (MDGI) Gene: Genomic Structure and Mutation Analysis in Human Breast Tumors. Genomics, 1996, 36, 377.	1.3	1
460	Enhancement of the Anti-Neoplastic Effects of Tamoxifen by Somatostatin Analogues. Digestion, 1996, 57, 29-33.	1.2	15
461	Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells. Journal of Biological Chemistry, 1996, 271, 1016-1021.	1.6	190
462	Enhancement of the Antineoplastic Effects of Tamoxifen by Somatostatin Analogues. , 1996, , 359-368.		6
463	Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer, 1995, 75, 23-28.	2.0	58
464	HH2A, an immortalized bovine mammary epithelial cell line, expresses the gene encoding mammary derived growth inhibitor (MDGI). In Vitro Cellular and Developmental Biology - Animal, 1995, 31, 25-29.	0.7	23
465	Re: Mutagen Sensitivity as a Risk Factor for Second Malignant Tumors Following Malignancies of the Upper Aerodigestive Tract. Journal of the National Cancer Institute, 1995, 87, 458-458.	3.0	1
466	Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: Correlations with effects on proliferation: A review. Progress in Growth Factor Research, 1995, 6, 495-501.	1.7	12
467	Metastatic Behavior of the RIF-1 Murine Fibrosarcoma: Inhibited by Hypophysectomy and Partially Restored by Growth Hormone Replacement. Journal of the National Cancer Institute, 1994, 86, 628-632.	3.0	11
468	Insulin-like Growth Factor Binding Protein 3 (IGF-BP3) Inhibits Estrogen-Stimulated Breast Cancer Cell Proliferation. Biochemical and Biophysical Research Communications, 1994, 198, 292-297.	1.0	66

#	Article	IF	CITATIONS
469	Enhancement of Tamoxifen-Induced Suppression of Insulin-Like Growth Factor I Gene Expression and Serum Level by a Somatostatin Analogue. Biochemical and Biophysical Research Communications, 1994, 203, 253-259.	1.0	52
470	In-vitro fertilisation and family history of breast cancer. Lancet, The, 1994, 344, 610-611.	6.3	10
471	The Human Insulin-like Growth Factor-Binding Protein 4 Gene Maps to Chromosome Region 17q12-q21.1 and Is Close to the Gene for Hereditary Breast-Ovarian Cancer. Genomics, 1993, 18, 414-417.	1.3	17
472	Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. European Journal of Cancer, 1993, 29, 1368-1372.	1.3	44
473	Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. European Journal of Cancer, 1992, 28, 788-793.	1.3	40
474	Potential role for somatostatin analogues in breast cancer: Rationale and description of an ongoing trial. Metabolism: Clinical and Experimental, 1992, 41, 119-120.	1.5	4
475	Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Research and Treatment, 1992, 22, 91-100.	1.1	100
476	Trimetrexate in untreated and previously treated patients with metastatic breast cancer: A cancer and leukemia group b study. Medical and Pediatric Oncology, 1991, 19, 283-288.	1.0	9
477	A Mathematical Model Describing Consequences of Abnormally High Levels of Epidermal Growth Factor Receptor on the Proliferation of Neoplastic Cells. Cancer Investigation, 1991, 9, 513-520.	0.6	3
478	Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. Cancer Chemotherapy and Pharmacology, 1990, 26, 457-460.	1.1	11
479	Insulinlike Growth Factor I: A Potent Mitogen for Human Osteogenic Sarcoma. Journal of the National Cancer Institute, 1990, 82, 301-305.	3.0	94
480	Combination chemotherapy with carboplatin and bleomycin for advanced and recurrent head and neck cancer: A phase II study. Journal of Surgical Oncology, 1988, 39, 215-216.	0.8	4
481	Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. Biochemical and Biophysical Research Communications, 1988, 154, 326-331.	1.0	71
482	Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Letters, 1987, 38, 223-230.	3.2	131
483	MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochemical and Biophysical Research Communications, 1985, 128, 898-905.	1.0	300
484	Amplified, overexpressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. Biochemical and Biophysical Research Communications, 1985, 131, 207-215.	1.0	76
485	Computer-aided information management systems in clinical trials. Computer Programs in Biomedicine, 1983, 16, 243-251.	0.8	10
486	The insulin–insulin-like growth-factor receptor family as a therapeutic target in oncology. , 0, , 110-118.		0

#	Article	IF	CITATIONS
487	Tissue-Specific Targeting of the Pthrp Gene: The Generation of Mice with Floxed Alleles. , 0, .		13
488	Translational and HIF11-Dependent Metabolic Reprograming Underpin Oncometabolome Plasticity and Synergy Between Oncogenic Kinase Inhibitors and Biguanides. SSRN Electronic Journal, 0, , .	0.4	1
489	A Hydride Transfer Complex Reprograms NAD Metabolism Preventing Senescence. SSRN Electronic Journal, 0, , .	0.4	Ο